Valneva SE Announces New Share Issue in 60 Million Euro Private Placement

Saint-Herblain, France, September 12, 2024 - Valneva SE (VALN), a company that specializes in the development of vaccines for infectious diseases, has announced plans for a significant capital increase through a private placement. The specialty vaccine company aims to raise roughly 60 million euros by issuing around 22.6 million new ordinary shares. This strategic move is designed to bolster Valneva's capital structure and support its continued growth and vaccine development efforts.

Details on the Private Placement

The private placement is subject to prevailing market conditions and entails the issuance of new ordinary shares. This infusion of capital is expected to provide Valneva with the financial flexibility necessary to further its mission in addressing unmet medical needs through prophylactic vaccines. The offering size equates to a substantial increase in the company's equity, reflecting investor confidence and the potential of Valneva's vaccine portfolio.

Valneva's Market Position and Prospects

Valneva SE, with its headquarters in Saint-Herblain, France, continues to play a pivotal role in the global healthcare market with its focus on vaccines for infectious diseases. The proposed capital increase through the new share issue demonstrates the company's commitment to expanding its reach and enhancing its ability to respond to the pressing needs in vaccine development. Valneva's position in the market is further solidified by the support of investors willing to participate in the private placement, highlighting the company's promising outlook.

Valneva, Shares, Placement